MorphoSys AG (MOR.DE)
- EQS Group
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys AG / Key word(s): AgreementMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 14.06.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, South San Francisco, United States, June 14, 2022MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 Human Immunology Biosciences (HIBio) is a biotechnology company focused
- Zacks
MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer
MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.
- EQS Group
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: MorphoSys AG / Key word(s): Agreement/MiscellaneousPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 13.06.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNew York, New York, U.S.; Boston, Massachusetts, U.S.; and Wilmington, Delaware, U.S., June 13, 2022Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboratio
